Anzeige
Meldung des Tages: DiagnosTear Technologies: Zwei Durchstarter für 2026?!

Dynavax Technologies Aktie News

Aktie
WKN:  A12EV9 ISIN:  US2681582019 US-Symbol:  DVAX Branche:  Pharmazeutika Land:  USA
15,38 $
+0,00 $
0,00%
13,065 € 26.12.25
Depot/Watchlist
Marktkapitalisierung *
1,11 Mrd. €
Streubesitz
0,81%
KGV
70,94
Index-Zuordnung
-

Dynavax Technologies News

24.12.25 - dpa-AFX
Sanofi will US-Impfstoffhersteller Dynavax für 2,2 Milliarden Dollar kaufen
Der Pharmakonzern Sanofi will den US-​Impfstoffhersteller Dynavax für gut zwei Milliarden Dollar kaufen. Das Gebot liege bei 15,50 US-Dollar je Aktie in bar, teilten die Franzosen am ...
24.12.25 - PR Newswire
Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders
Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders PR Newswire
24.12.25 - wallstreetONLINE Redaktion
Keine ruhigen Festtage: Übernahme-Hammer an Heiligabend: Milliardendeal in der Pharmabranche!
Der französische Pharmakonzern Sanofi hat an Heiligabend die Übernahme des US-​Biotechnologiekonzerns Dynavax Technologies bekanntgegeben. Trotz Weihnachten: Dank ...
24.12.25 - PR Newswire
Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline
Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline PR Newswire
19.11.25 - PR Newswire
Dynavax to Participate at the 8th Annual Evercore Healthcare Conference
Dynavax to Participate at the 8th Annual Evercore Healthcare Conference PR Newswire
05.11.25 - PR Newswire
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program PR Newswire
05.11.25 - PR Newswire
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program PR Newswire
22.10.25 - PR Newswire
Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025
Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025 PR Newswire
21.10.25 - PR Newswire
Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial
Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial PR Newswire
27.08.25 - PR Newswire
Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference
Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference PR Newswire
21.08.25 - PR Newswire
Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile
Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-​in-Class Shingles Vaccine Profile PR Newswire
07.08.25 - PR Newswire
Dynavax Reports Second Quarter 2025 Financial Results
Dynavax Reports Second Quarter 2025 Financial Results PR Newswire
29.07.25 - PR Newswire
Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 PR Newswire
11.06.25 - PR Newswire
Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting
Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting PR Newswire
09.06.25 - PR Newswire
Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting
Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting PR Newswire
04.06.25 - PR Newswire
Dynavax Comments on Glass Lewis Recommendation
Dynavax Comments on Glass Lewis Recommendation PR Newswire
28.05.25 - PR Newswire
Dynavax to Present at William Blair's 45th Annual Growth Stock Conference
Dynavax to Present at William Blair's 45th Annual Growth Stock Conference PR Newswire
23.05.25 - PR Newswire
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees PR Newswire
12.05.25 - PR Newswire
Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value
Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value PR Newswire
07.05.25 - PR Newswire
/C O R R E C T I O N -- Dynavax Technologies/
/C O R R E C T I O N -- Dynavax Technologies/ PR Newswire

Newssuche

Videos

newspaper
26.12.25
Viper Strike Strategie Intro
Strategie-​Paket inklusive Live Online-​Schulung am 4.1. JETZT buchbar ... Mehr »
Anzeige

Aktie im Fokus

DiagnosTear Technologies
DiagnosTear Technologies Inc
0,352 €
-3,83%
DiagnosTear Technologies Inc Chart
Zwei Durchstarter für 2026?!
Mehr zur Aktie »